Julia Haas

This inventor holds 64 USPTO granted patents and 14 published patent applications, plus 14 CIPO patents and 23 EPO patents, primarily in RET Kinase Inhibitors (CPC class C07D). Top assignees: Array Biopharma Inc., Loxo Oncology, Inc., Eli Lilly and Company. Active years: 2008-2024.

USPTO Granted Patents = 64 (Patent Applications = 14)

% Patents Active = 89.1

CIPO Patents = 14 (Patent Applications = 8)

EPO Patents = 23 (Patent Applications = 30)

Average Co-Inventor Count = 6.9

ph-index = 17

Forward Citations = 882(Granted Patents)

Forward Citations (Not Self Cited) = 394(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Boulder, OH (US) (2018)
Boulder, CO (US) (2008 - 2024)
Indianapolis, IN (US) (2024)

Company Filing History:

Eli Lilly and Company

Mirati Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2008-2024

Loading Chart...

Areas of Expertise:

RET Kinase Inhibitors

Pyrazolo Compounds

Macrocyclic Compounds

Trk Kinase Inhibitors

KRas G12C Inhibitors

Substituted Pyrimidines

Bicyclic Urea

Pyrrolidinyl Compounds

Fused Heterocycles

Imidazo Compounds

Crystalline Forms

Pain Treatment

64 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),

2. 11964988 - Fused heterocyclic compounds as RET kinase inhibitors (2024-04-23),

3. 11851434 - Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors (2023-12-26),

4. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2023-05-16),

5. 11603374 - Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors (2023-03-14),

6. 11524963 - Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors (2022-12-13),

7. 11472802 - Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors (2022-10-18),

8. 11267818 - Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds (2022-03-08),

9. 11214571 - Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof (2022-01-04),

10. 11168090 - Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors (2021-11-09),

11. 11091486 - Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof (2021-08-17),

12. 10966985 - Macrocyclic compounds as ROS1 kinase inhibitors (2021-04-06),

13. 10953005 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2021-03-23),

14. 10889589 - Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain (2021-01-12),

15. 10881652 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2021-01-05),

Title: The Innovative Contributions of Julia Haas in Pharmaceutical Patents

Introduction

Julia Haas, based in Boulder, CO, is a prolific inventor with an impressive portfolio that includes 64 patents. Her work predominantly focuses on the development of compounds that serve as inhibitors for RET kinase, which plays a significant role in various diseases and disorders.

Latest Patents

Among her latest patents, she has developed “Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors.” This invention presents a range of compounds indicated for the treatment and prevention of RET-associated diseases. Similarly, her patent on “Fused heterocyclic compounds as RET kinase inhibitors” also outlines effective compounds for similar therapeutic applications. Both patents highlight her expertise in creating pharmaceutically acceptable salts and solvates with specific structural characteristics that target RET kinase.

Career Highlights

Julia has had a significant impact through her career at leading companies in the biotechnology sector, including Array Biopharma Inc. and Loxo Oncology, Inc. Her insights and innovations have greatly contributed to advancements in targeted cancer therapies.

Collaborations

Throughout her career, Julia Haas has collaborated with notable professionals such as Yutong Jiang and Steven Wade Andrews. These partnerships have enabled the successful development and patenting of various innovative compounds.

Conclusion

Julia Haas exemplifies the spirit of innovation in the pharmaceutical field, with her substantial contributions as an inventor. Her ongoing research and patents not only advance scientific understanding but also pave the way for new therapeutic possibilities for patients suffering from RET-associated diseases.